Bristol-Myers Squibb

Update in progress

BMY (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Bristol-Myers Squibb discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide across oncology, hematology, immunology, cardiovascular, neuroscience, and related fields. It markets Opdivo, Opdivo Qvantig (subcutaneous PD-1 inhibitor for solid tumors), Orencia, Yervoy, Zeposia, Abecma, Sotyktu, Krazati, Camzyos, Cobenfy, Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane, Augtyro, and more. Headquartered in Princeton, NJ; founded 1887.

Company score

Sentiment: 1.03; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.28; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.31; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.59; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive